July 7, 2022 , at about 10 am , Qing Wang, Party Secretary of Zhangjiang Town, and Li Guan, Deputy Mayor of Zhangjiang Town, and several others visited Shanghai Xihua Scientific Co., Ltd. to carry out large-scale investigations named ‘Epidemic, Economy ,Safety’, Xihua General Manager Xiaohang Shen, Executive Vice President Hao Li, Vice President of Operations Lanjin Qu and other representatives accompanied.

The 2022 Chinese Pharmaceutical Association Pharmaceutical Bioanalysis Society (hereinafter referred to as CBF) was officially held on June 17. The venue was divided into a main venue and three sub-venues: DMPK sub-venue, bioanalysis sub-venue and biomarker sub-venue. From 13:30 to 14:00 on June 19, Dr. Li Zhiyan, Director of Bioanalysis of Xihua Biopharmaceuticals, will give a keynote report on "Bioanalysis Strategies of AAV Gene Therapy Drugs" at the bioanalysis venue.

In March 2022, the epidemic broke out suddenly in Shanghai. On the 14th of the same month, Shanghai Xihua Scientific Co., Ltd. (Xihua) urgently convened volunteers to set up a Xihua nucleic acid testing team and set out for front-line support. This expedition is urgent!

On February 17, 2022, Zheyuan Jiang and Wei Xu visited Xihua. Dr. Xing, Chairman of Xihua , and Dr. Gong, CEO of XihuaPharma, together with other relevant department heads, attended the symposium and accompanied them during the visit.

莫西沙星（moxifloxacin）是一种新型超广谱喹诺酮类抗菌药，对革兰阳性菌、革兰阴性菌、衣原体和支原体均有良好的抗菌活性。因其具有抗菌性强、抗菌谱广、不良反应少等特点，在临床上被广泛应用于治疗金黄色葡萄球菌、流感杆菌、肺炎球菌等引起的获得性肺炎、慢性支气管炎、急性咽炎、急性鼻窦炎以及急性扁桃体炎等。